Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2013

View Archived Issues

Researchers discover novel urinary biomarker of membranous nephropathy

Investigators present preclinical data for (+)-[18F]flubatine

Tigatuzumab evaluated in patients with triple-negative breast cancer

First-in-human data for SYK inhibitor P505-15

Faldaprevir/BI-207127/ribavirin HCV treatment regimen analyzed in phase II trial

Novel PKB/c-Akt inhibitors synthesized by Array BioPharma and Genentech

Biosortia collaborates to discover natural products for infectious disease

Sea Lane grants Takeda access to ConCIRT libraries for use in drug discovery

First patient enrolled in global phase IIb study of rostafuroxin

Ataluren demonstrates sustained effects over time in patients with nmCF

Amrita Therapeutics discloses novel antiviral proteins

Nerviano Medical Sciences presents new PARP inhibitors

New PKC-iota inhibitors synthesized at Cancer Research Technology and Cephalon

Verastem receives orphan medicinal product designation in Europe for VS-6063

Omeros cleared to begin phase I trial of OMS-721

Bionor Pharma completes first part of phase II study combining Vacc-4x with Revlimid

Epizyme enrolls first patient in phase I/II trial of EPZ-6438

Northwest Biotherapeutics begins phase I/II trial of DCVax-Direct in solid tumors

Lilly's BACC study in Alzheimer's disease terminated

Xoma begins pilot trial of gevokizumab in patients with pyoderma gangrenosum

Safety monitoring board recommends continuation of VALOR trial

FDA approves Xgeva to treat giant cell tumor of bone

Cangene withdraws IB-1001 MAA, plans to resubmit

Astellas launches Xtandi in Canada for castration-resistant prostate cancer

First phase II results of novel cPLA2 inhibitor for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...